Abstract
A priority in preventive cardiology is to reduce the number of recurrent events and to prolong survival in patients with established coronary heart disease (CHD). Aim of the present study was to examine risk factors for long-term mortality in CHD patients who entered routine secondary prevention after a coronary event or intervention. Such patients, from the EUROASPIRE (EUROpean Action on Secondary Prevention through Intervention to Reduce Events) I and II studies in the region of Münster, Germany, were followed over a mean period of 8.0 years up to the end of 2005. Patients were up to 70 years of age at baseline when they were interviewed and examined using standardised methods. Baseline examination was carried out at least 6 months and at a mean of 19.5 months after the coronary event or procedure. In 367 patients from EUROASPIRE I and 380 patients from EUROASPIRE II, a total of 125 deaths (16.7%) occurred during follow-up. Multivariate analyses, using Cox proportional hazards models, established diabetes mellitus and smoking as predictors for all-cause mortality with estimated hazard rate ratios (HRRs) of 2.24 (95% confidence interval (CI): 1.43–3.49) and 1.95 (95% CI: 1.23–3.10), respectively. Significant associations were found between diabetes mellitus and cardiovascular (HRR 2.36; 95% CI: 1.31–4.24) as well as CHD mortality (HRR 2.40; 95% CI: 1.25–4.59). Systolic blood pressure was significantly associated with increased cerebrovascular disease mortality (HRR 1.04; 95% CI: 1.01 and 1.08 for 1 mmHg increase). In conclusion, long-term mortality in coronary patients from routine secondary prevention is substantial. Diabetes mellitus and smoking represent key issues in patients with established CHD.
Similar content being viewed by others
Abbreviations
- BMI:
-
Body mass index
- CABG:
-
Coronary artery bypass graft
- CHD:
-
Coronary heart disease
- CVD:
-
Cardiovascular disease
- DALYs:
-
Disability adjusted life years
- EUROASPIRE:
-
EUROpean Action on Secondary Prevention through Intervention to Reduce Events
- HDL:
-
High density lipoprotein
- HRR:
-
Hazard rate ratio
- OR:
-
Odds ratio
- PTCA:
-
Percutaneous transluminal coronary angioplasty
- RCT:
-
Randomized controlled trial
- WHO:
-
World Health Organisation
References
Lopez AD, Murray CC. The global burden of disease, 1990–2020. Nat Med. 1998;4:1241–3. doi:10.1038/3218.
World Health Organisation. World Health Report 2004. Geneva: World Health Organisation; 2004.
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Fourth Joint European Societies’ Task Force on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehabil. 2007;14:S1–113.
Chambless L, Keil U, Dobson A, et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985–1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. Circulation. 1997;96:3849–59.
Marschner IC, Colquhoun D, Simes RJ, et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol. 2001;38:56–63. doi:10.1016/S0735-1097(01)01360-2.
Wilhelmsen L, Pyorala K, Wedel H, et al. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J. 2001;22:1119–27. doi:10.1053/euhj.2000.2481.
EUROASPIRE Study Group. EUROASPIRE: European action on secondary prevention through intervention to reduce events. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997;18:1569–82.
EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554–72. doi:10.1053/euhj.2001.2610.
De Bacquer D, De Backer G, Ostor E, et al. Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. Eur J Cardiovasc Prev Rehabil. 2003;10:289–95. doi:10.1097/00149831-200308000-00012.
Leander K, Wiman B, Hallqvist J, et al. Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP). Eur J Cardiovasc Prev Rehabil. 2007;14:532–7. doi:10.1097/HJR.0b013e328012e3cc.
Völzke H, Henzler J, Menzel D, et al. Outcome after coronary artery bypass graft surgery, coronary angioplasty and stenting. Int J Cardiol. 2007;116:46–52. doi:10.1016/j.ijcard.2006.02.008.
Kaplan RC, Heckbert SR, Furberg CD, et al. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol. 2002;55:654–64. doi:10.1016/S0895-4356(02)00405-5.
Wong ND, Cupples LA, Ostfeld AM, et al. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol. 1989;130:469–80.
Enbergs A, Liese A, Heimbach M, et al. Evaluation of secondary prevention of coronary heart disease. Results of the EUROASPIRE study in the Münster region. Z Kardiol. 1997;86:284–91. doi:10.1007/s003920050060.
Heidrich J, Liese AD, Kalic M, et al. Secondary prevention of coronary heart disease Results from EUROASPIRE I and II in the region of Münster, Germany. Dtsch Med Wochenschr. 2002;127:667–72. doi:10.1055/s-2002-23480.
EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357:995–1001. doi:10.1016/S0140-6736(00)04235-5.
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6. doi:10.1016/0197-2456(96)00075-X.
Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706. doi:10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O.
Hosmer DW, Lemeshow S. Applied survival analysis. Regression modeling of time to event data. New York: John Wiley & Sons; 1999.
MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–74. doi:10.1016/0140-6736(90)90878-9.
Boshuizen HC, Lanti M, Menotti A, et al. Effects of past and recent blood pressure and cholesterol level on coronary heart disease and stroke mortality, accounting for measurement error. Am J Epidemiol. 2007;165:398–409. doi:10.1093/aje/kwk021.
Husten CG, Shelton DM, Chrismon JH, et al. Cigarette smoking and smoking cessation among older adults: United States, 1964–94. Tob Control. 1997;6:175–80.
Junge B, Nagel M. Smoking behavior in Germany. Gesundheitswesen. 1999;61:S121–5.
Acknowledgments
We thank all patients for participation in the study. We also thank the European Society of Cardiology (ESC), Sophia Antipolis, France, for financial support in EUROASPIRE I and II. Unrestricted educational grants were obtained from MSD Sharp & Dohme, Haar (EUROASPIRE I), and Pfizer, Karlsruhe and AstraZeneca, Wedel/Holstein (EUROASPIRE II).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prugger, C., Wellmann, J., Heidrich, J. et al. Cardiovascular risk factors and mortality in patients with coronary heart disease. Eur J Epidemiol 23, 731–737 (2008). https://doi.org/10.1007/s10654-008-9291-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-008-9291-x